Vittorio Fusco

7PUBLICATIONS
20CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersDental therapeutics, pharmacology and toxicologyMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jun 24, 2026
Prevalence of medication-related osteonecrosis of the jaw (MRONJ) in breast cancer patients receiving low-dose bone modifying agents for cancer treatment-induced bone loss (CTIBL): need for further data.

|Sep 15, 2025
The use of bone-modifying agents in early breast cancer: AIOM Guidelines update and perspectives.

Alberto Zambelli, Riccardo Gerosa, Michela Cinquini

|Jul 26, 2022
Prognosis of metastatic bone cancer and myeloma patients and long-term risk of medication-related osteonecrosis of the jaw (MRONJ): some critical points.

Vittorio Fusco, Maura Rossi, Antonella Fasciolo

|Mar 21, 2022
One changing and challenging scenario: the treatment of cancer patients with bone metastases by bisphosphonates and denosumab, the cost-benefit evaluation of different options, and the risk of medication-related osteonecrosis of the jaw (MRONJ).

Vittorio Fusco, Giuseppina Campisi, Alberto Bedogni

|Mar 16, 2022
The preventive care of medication-related osteonecrosis of the jaw (MRONJ): a position paper by Italian experts for dental hygienists.

Rodolfo Mauceri, Rita Coniglio, Antonia Abbinante

|Nov 08, 2017
Incidence of osteonecrosis of the jaw (ONJ) in cancer patients with bone metastases treated with bisphosphonates and/or denosumab: some comments and questions.

Vittorio Fusco, Maura Rossi, Iolanda De Martino

Pageof 2

Frequent Collaborators

1 joint publications

R Gerosa

1 joint publications

M Di Maio

1 joint publications

F Miglietta

1 joint publications

L Arecco